NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/17/2024
Back to search
Official data from USPTO
XEOMIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
04/03/2026
Trademark type
Word
Nice classes
5, 10
Filing date
02/22/2023
Registration date
09/17/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/17/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
DE
Examiner
JAGDEO, KARA CECILIA
Law office
N30
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Merz Pharma GmbH & Co. KGaA
Representatives
Jeff Van Hoosear Knobbe, Martens, Olson & Bear, LLP
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical products for use in dermatology in the aesthetic field; pharmaceutical products for relaxing muscles; pharmaceutical products for the treatment of wrinkles and facial fines and for the treatment of cerebral and neurological disordersdiseases and conditions; medical products for use in dermatology in the aesthetic fieldmedicated dermatological preparations and substances; medical products for relaxing musclesmuscle relaxants; medical products in the nature of botulinum toxin for the treatment of wrinkles and facial lines and the treatment of cerebral and neurological disordersdisease and conditions; medicaments for human medical use for the treatment of cerebral and neurological disordersdiseases and conditions; prefilled syringes sold filled with botulinum toxin for medical and pharmaceutical use in dermatology in the aesthetic fieldfor relaxing musclesfor the treatment of wrinkles and facial lines and for the treatment of cerebral and neurological disordersdiseases and conditions
Class 10
Medical apparatus and instruments for medical use in dermatological procedures; hypodermic needles; hypodermic needles for injections; syringes for medical purposes; systems for injections consisting of hypodermic needles for injections; syringes for medical purposes and injection devices for pharmaceuticals in the nature of botulinum toxin; injection equipment for single dosesneedles for injections; containers for the administration of medicinescontainers for botulinum toxin
Publications
History of USPTO decisions and trademark events.
19 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
09/17/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/25/2024
PUBO
PUBLISHED FOR OPPOSITION
06/25/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/18/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/29/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/29/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/29/2024
RFNT
REFUSAL PROCESSED BY IB
02/14/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
01/19/2024
RFRR
REFUSAL PROCESSED BY MPU
01/19/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
12/02/2023
CNRT
NON-FINAL ACTION WRITTEN
12/01/2023
DOCK
ASSIGNED TO EXAMINER
11/21/2023
MAFR
APPLICATION FILING RECEIPT MAILED
07/11/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/07/2023
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
07/03/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/15/2023
Continuous trademark protection
Get notified about every new filing that threatens XEOMIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.